Last reviewed 2026-04-19 · How we verify

SHP611

Shire · Phase 2 active Small molecule

At a glance

Generic name	SHP611
Also known as	HGT-1110, TAK-611, recombinant human arylsulfatase A [rhASA]
Sponsor	Shire
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SHP611 CI brief — competitive landscape report
SHP611 updates RSS · CI watch RSS
Shire portfolio CI